The government has approved a 30 per-cent trade margin cap on non-scheduled anti-cancer drugs, a move expected to reduce prices by up to 70% and save patients an estimated Rs 2,500 crore annually. An expert committee will finalise the medicines covered.
The government has expanded price controls on non-scheduled anti-cancer medicines by capping trade margins at 30 per cent of MRP. The move could reduce prices by up to 70 per cent, saving patients an estimated Rs 2,500 crore annually
